
==== Front
NPJ Vaccines
NPJ Vaccines
NPJ Vaccines
2059-0105
Nature Publishing Group UK London

963
10.1038/s41541-024-00963-4
Article
CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice
Yue Xinyu 1
Zhong Cailing 2
Cao Rui 1
Liu Sizhe 1
Qin Zhiran 3
Liu Lin 1
Zhai Yanmei 1
Luo Wanyu 1
Lian Yikai 3
Zhang Mengjie 3
Lu Hongjie 1
Wang Yuanyuan 1
Xu Mengxin 1
Liu Shuning 1
Lv Kexin 1
Sun Yuzhu 1
Zhu Xingchen 1
Mai Haoting 1
Liao Jing 4
Yang Jingyi 5
Deng Lei 6
Liu Yang 3
http://orcid.org/0000-0002-2000-7053
Sun Caijun 1
http://orcid.org/0000-0002-4110-4776
Zheng Ke-Wei zhengkewei@hnu.edu.cn

7
http://orcid.org/0000-0001-9279-0916
Shu Yuelong shuylong@mail.sysu.edu.cn

18
http://orcid.org/0000-0002-4659-1550
Chen Yao-Qing chenyaoqing@mail.sysu.edu.cn

1910
1 https://ror.org/0064kty71 grid.12981.33 0000 0001 2360 039X School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China
2 https://ror.org/0064kty71 grid.12981.33 0000 0001 2360 039X School of Pharmaceutical Sciences, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China
3 grid.510951.9 0000 0004 7775 6738 Institute of Infectious Disease, Shenzhen Bay Laboratory, Shenzhen, Guangdong China
4 https://ror.org/00zat6v61 grid.410737.6 0000 0000 8653 1072 GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China
5 grid.8547.e 0000 0001 0125 2443 Vaccine and Immunology Research Center, Translational Medical Research Institute, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
6 https://ror.org/05htk5m33 grid.67293.39 Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha, China
7 https://ror.org/05htk5m33 grid.67293.39 School of Biomedical Sciences, Hunan University, Changsha, China
8 grid.506261.6 0000 0001 0706 7839 Key Laboratory of Pathogen infection prevention and control (Peking Union Medical College, Ministry of Education), State Key Laboratory of Respiratory Health and Multimorbidity, National Institute of Pathogen Biology of Chinese Academy of Medical Science (CAMS)/ Peking Union Medical College (PUMC), Beijing, China
9 https://ror.org/03m01yf64 grid.454828.7 0000 0004 0638 8050 Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, China
10 Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety, Shenzhen, China
16 9 2024
16 9 2024
2024
9 1706 4 2024
1 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Developing broad-spectrum influenza vaccines is crucial for influenza control and potential pandemic preparedness. Here, we reported a novel vaccine design utilizing circular RNA (circRNA) as a delivery platform for multi-subtype neuraminidases (NA) (influenza A N1, N2, and influenza B Victoria lineage NA) immunogens. Individual NA circRNA lipid nanoparticles (LNP) elicited robust NA-specific antibody responses with neuraminidase inhibition activity (NAI), preventing the virus from egressing and infecting neighboring cells. Additionally, the administration of circRNA LNP induced cellular immunity in mice. To achieve a universal influenza vaccine, we combined all three subtypes of NA circRNA-LNPs to generate a trivalent circRNA vaccine. The trivalent vaccine elicited a balanced antibody response against all three NA subtypes and a Th1-biased immune response in mice. Moreover, it protected mice against the lethal challenge of matched and mismatched H1N1, H3N2, and influenza B viruses, encompassing circulating and ancestral influenza virus strains. This study highlights the potential of delivering multiple NA antigens through circRNA-LNPs as a promising strategy for effectively developing a universal influenza vaccine against diverse influenza viruses.

Subject terms

Pathogenesis
RNA vaccines
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 31970881, 92169104 Chen Yao-Qing issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Hemagglutinin (HA) and neuraminidase (NA) are the two major glycoproteins on the influenza envelope. NA is the second most abundant glycoprotein on the influenza virus envelope and promotes virus release during the influenza replication cycle1,2. The current effectiveness of the influenza vaccine is primarily demonstrated by its ability to induce hemagglutination inhibition antibody responses. However, seasonal influenza viruses often exhibit significant immune evasion against such immune responses. In recent years, there has been increasing recognition of the crucial role of NA-specific immunity in conferring cross-protection1–3. NA has a slower mutation rate than HA proteins, which are prone to rapid antigenic drift4. Our previous work revealed that natural influenza virus infection induces a significant proportion of NA-reactive B cells and broadly neutralizing NA antibodies in humans5. These NA-reactive antibodies demonstrated robust NA inhibitory activity in vitro, protecting mice from lethal challenge. Additionally, recent studies have identified a large number of conserved neutralizing epitopes on NA6–10. Studies in guinea pigs and humans have shown that anti-NA immunity can hinder viral transmission11–13. Thus, NA could be a potential target for broad-spectrum influenza vaccine development.

However, licensed influenza vaccines have not sufficiently induced a robust NA-specific antibody response5. This may be attributed to the absence of sufficient NA components in the vaccines or their degradation during production. Attempts to address this challenge include incorporating recombinant NA protein into seasonal vaccines14–16, manipulating viral packaging signals to increase NA content17, and extending NA stalk length on the virus particles to enhance NA immunogenicity18. Notably, mRNA technology offers a unique advantage by delivering membrane-bound NA in their native conformation, which has shown promising results in inducing potent anti-NA immunity in mice19,20. Vaccination with an NA mRNA vaccine can induce NA-reactive antibodies, including NA inhibition (NAI), antibody-dependent cellular cytotoxicity (ADCC) antibodies, and cellular immune response20–22.

Circular RNA (circRNA) is a class of covalently closed ring RNA molecules generated by RNA splicing in eukaryotic cells. CircRNA lacks exposed 3’ and 5’ ends, making it resistant to degradation by most nucleases. This stability provides an advantage over linear RNA, such as mRNA. Incorporating internal ribosome entry site (IRES) allows circRNA to facilitate long-lasting protein expression23. CircRNA vaccines encoding the receptor-binding domain (RBD) have demonstrated efficacy against SARS-CoV-2 variants (Delta and Omicron) in mice and rhesus monkeys24. In addition to stability, circRNA possesses potent adjuvant properties. They can effectively activate intracellular sensors like RIG-I and MDA5, promoting the maturation of dendritic cells (DCs) and triggering robust immune responses25. Studies have shown a rapid increase in proinflammatory factors and chemokines following circRNA injection, leading to significant recruitment of immune cells (DCs, monocytes, and macrophages) to the injection site. Long-lasting and robust T cell responses were observed in mice immunized with circRNA encoding OVA25. T cells targeting conserved epitopes can provide an additional layer of protection when the virus escapes antibodies26–28. These combined attributes position circRNA as a promising platform for developing next-generation, broadspectrum influenza vaccines.

Here, we designed circRNA vaccines containing N1, N2, and influenza B virus NA antigens to elicit broad-spectrum NA immunity against heterologous influenza. This trivalent circRNA vaccine successfully induced robust NA-specific humoral and cellular immunity in mice. Moreover, it protected mice against lethal challenges with homologous and heterologous strains of H1N1, H3N2, and Victoria lineage influenza B viruses. These findings provide compelling evidence that the NA-targeting circRNA vaccine holds considerable promise for achieving broad-spectrum protection against influenza in mice and can be considered a novel strategy for potential universal influenza vaccine development.

Results

Preparation and characterization of circRNA-NA Vaccines

NA from three circulating seasonal influenza vaccine strains were selected: A/Michigan/45/2015 (H1N1), A/Switzerland/9715293/2013 (H3N2), and B/Florida/12/2017 (Victoria) (Fig. 1a and Fig. S1). These strains were selected because they predominated in recent seasons. The vaccine did not include the Yamagata lineage virus NA as it has been rarely detected since 202029. CircRNAs encoding the selected NAs were synthesized using the permuted intron-exon (PIE) splicing strategy and subsequently encapsulated into lipid nanoparticles (LNPs) via an iNanoE microfluidic system. Sanger sequencing confirmed accurate ligation of the circRNAs (Fig. 1b). Gel electrophoresis demonstrated that circRNA can resist the hydrolysis by RNase R. (Fig. 1c). All prepared LNPs exhibited consistent characteristics, with ~80 nm particle size and polydispersity indices (PDI) < 0.2. The encapsulation efficiency of these LNPs exceeded 93% (Fig. 1e).Fig. 1 Design and characterization of circRNA-LNP encoding NA.

a Schematic diagram of circRNA vaccine production. Linear RNA precursors encoding N1, N2, and IBV NA were self-spliced by group I catalytic intron to form circRNA. CircRNA was then encapsulated into lipid nanoparticles (LNP). The figure was created by the author using Adobe Illustrator 2020. b Verify the self-splicing junction site of circRNA using Sanger sequencing of the junction site after reverse transcription and PCR amplification. c CircRNA and linear precursor were separated on 1.5% agarose gel. Lane L: Linear precursor. Lane L + R: Linear precursor digested with RNase R. Lane C: circRNA not digested with RNase R. Lane C + R: circRNA digested with RNase R. d MUNANA assay for measuring NA enzyme activity in LNP-transfected cells. The curve shows the fluorescence intensity versus the density of cells in 50 μL. Data was shown as means of four repeated experiments ± SD. e Dynamic light scattering (DLS) to characterize the particle size and dispersion of circRNA-LNP. Representative images of each LNP were shown. f Frequency of NA expression in 293 T cells transfected with NA LNP, Blank LNP as a negative control. IRES: internal ribosome entry site. E1: exon fragment 1 upstream of 5’intron. E2: exon fragment 2 downstream of 3’intron.

To evaluate NA expression from circRNA, HEK293T cells were transfected with LNP-encapsulated circRNAs. The expression of NA antigens was confirmed by flow cytometry using a broad-spectrum NA antibody 1G0110, an N2-specific antibody 229-2C065, or an influenza B virus NA-specific antibody CC61 (isolated and identified by Prof. Chen’s laboratory). Analysis indicated stable NA expression in approximately 98% of transfected cells, indicating efficient protein translation from circRNAs (Fig. 1f). Furthermore, to verify whether the NA antigens produced by circRNA were functional, the cells transfected with circRNA-LNP were tested for NA activity using a 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) substrate. Positive enzyme activity confirmed the native conformation of NA antigens produced by circRNAs (Fig. 1d)30.

CircRNA-NA vaccines elicited robust immunity in mice

To evaluate the immunogenicity of circRNA vaccines in mice, groups of mice (n = 5) were administered two doses (10 μg or 2 μg for each dose, respectively) of each circRNA-NA, with a four-week interval between doses (Fig. 2a). Antibody titers were assessed after primary and booster vaccinations, revealing all three vaccines elicited significant increases in NA-specific antibody levels compared to the control group in a dose-dependent manner (Fig. 2b–d). For all the groups, serum titers significantly increased after booster immunization, with most animals exceeding 104 (Fig. 2b–d). The binding breadth of immune sera indicated that monovalent vaccines could induce specific antibodies against heterologous NAs within the same NA subtype (Fig. 2e–g). Given the potential link correlation between NAI antibody titers and protection13,31,32, NAI antibodies against homologous NA were evaluated. Boosting circRNA-NA administration significantly increased NAI titers (over 1000 or near 1000, except 2 μg dose in the N2 group, Fig. 2h–j). Suggesting that booster vaccination may be necessary to stimulate the maturation of NA-specific B cells and the production of functional antibodies. Therefore, a two-dose immunization regimen was adopted for subsequent studies.Fig. 2 Monovalent circRNA vaccine induces antibody response in mice.

a Five mice per group were immunized with two doses of monovalent circRNA vaccine (N1, N2, IBV) at a four-week interval. Sera were collected 3 weeks after both the prime and boost immunization. A blank LNP group was used as a control. The figure was created by the author using Adobe Illustrator 2020. Binding antibodies against Mich15 (b), SL32 (c), and BCOL17 (d) NA recombinant proteins were detected by ELISA. ELISA was performed to assess the binding ability of N1 monovalent (e), N2 monovalent (f), IBV monovalent (g) circRNA immune sera to heterologous N1, N2, IBV NA recombinant protein. The radar diagram shows the geometric mean titer (GMT) of each group (n = 5). The abbreviation of the virus strain was the same as in Fig. S1. NAI antibodies against Mich15 (h), SL32 (i), and BCOL17 (j) were detected by ELLA. Using recombinant protein as antigen. Neutralization titers of boost immune sera against CA09 (k), SL32 (l), and BCOL17 (m) virus were detected by microneutralization assay. Data are presented as the mean ± SD (n = 5), and each symbol represents one animal. The dashed lines correspond to the lowest initial dilution. Statistical significance was performed by One-way ANOVA; Unpaired Student’s t tests were used to compare antibody titers between prime and boost sera within the same dosage group of mice; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.

To further assess vaccine efficacy, a microneutralization assay (MN assay) was conducted to evaluate the sera’ capacity to inhibit virus replication in vitro. MN assay results confirmed that post-boost sera from all groups exhibited significant virus neutralization activity (Fig. 2k–m). Notably, the N2 groups demonstrated particularly strong neutralizing activity against the homologous A/Switzerland/9715293/2013 virus (MN titer ~1000, Fig. 2h). Since NA antibodies do not directly neutralize viral infection, it is plausible that the immune serum used in the MN experiments suppressed the virus by inhibiting viral release and subsequent infection of neighboring cells. Overall, the above data confirmed that circRNA vaccines containing NA antigens presented strong immunogenicity, inducing NAI and neutralizing antibodies in mice.

CircRNA-NA vaccine induced NA-specific T cell response in mice

In addition to eliciting robust humoral responses, cellular immunity was also instrumental in enhancing the protective efficacy of vaccines. Previous studies on nucleic acid vaccines, such as mRNA, have successfully induced antigen-specific T cell responses33–35. NA-specific T cell responses were evaluated by Enzyme-linked immunosorbent spot (ELISpot) assay. Results indicated that all three circRNA vaccines significantly increased the number of IFN-γ and IL-4 producing cells compared with the control group (Fig. 3a–e). These findings were further corroborated by intracellular cytokine staining (ICS) assays (Fig. 3f–h and Fig. S2).Fig. 3 CircRNA vaccination induced NA-specific cellular responses.

a–c Mice were vaccinated with 10 μg of circRNA-LNP encoding N1, N2, or IBV NA, following a prime-boost vaccination scheme. Ten days post boost vaccination, the spleen was harvested and spot-counting for IFN-γ/IL-4 -secreting cells by ELISpot assay after stimulating with N1 (a), N2 (b) or IBV NA (c) recombinant protein. Representative walls of IFN-γ (d) or IL-4 (e) ELISpot. The proportion of IFN-γ (f), TNF-α (g), or IL-2 (h) secreting CD4+ and CD8+ T cells was assessed by FASC. Splenocytes from the blank LNP group were used as a control. Data are presented as the mean ± SD (n = 5), and each symbol represents one animal. Statistical significance was performed by unpaired t test; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.

Upon stimulation with recombinant N1, N2, or influenza B virus (IBV) NA proteins, CD4+ T cells producing IFN-γ, TNF-α, and IL-2 were detected in mice that received the circRNA vaccine (Fig. 3f–h). IFN-γ-secreting CD8+ T cells were detected in mice immunized with circRNA-N1 and circRNA-IBV-NA (Fig. 3f, h). The proportion of IFN-γ-secreting CD8+ T cells was also observed in the group immunized with circRNA-N2, although there was no significant difference between the groups (P = 0.078) (Fig. 3g). Overall, these data demonstrate that the circRNA-NA vaccine can induce NA-specific T cell responses in mice, encompassing both CD4+ and CD8+ subsets.

Trivalent circRNA vaccine induced broad-spectrum immunity

Drawing from previous successes in delivering multivalent HA antigens via mRNA LNPs without encountering antigenic competition36, we developed a trivalent circRNA vaccine. This vaccine combines three distinct circRNA LNPs encoding N1, N2, and IBV antigens. This strategy aims to utilize multivalent antigen delivery to broaden the range of vaccine protection while mitigating antigenic interference. Mice were vaccinated with a combination of N1, N2, and IBV NA circRNA LNPs using two doses: 30 μg (10 μg each NA) and 6 μg (2 μg each NA), with a 4-week boost interval (Fig. 4a).Fig. 4 Trivalent circRNA vaccine induced a balanced immune response against N1, N2, and influenza B NA.

a Trivalent circRNA vaccine immunization and challenge regimen. Mice received a prime-boost immunization program with 4 weeks intervals, 4 weeks after boost vaccination mice were challenged with 5 × LD50 or 1 × LD50 influenza virus. Body weight and survival rate were monitored for 14 days. Some mice were euthanized, and lungs were collected at 4 dpi. A blank LNP group was used as a control. The figure was created by the author using Adobe Illustrator 2020. ELISA was used to measure the binding antibody titers against Mich15 (b), SL32 (c), and BCOL17 (d) in the serum samples from the trivalent vaccine group. e The binding breadth of trivalent vaccine immune sera after boost vaccination. The radar diagram shows each group’s geometric mean titer (GMT) (n = 5). The abbreviation of the virus strain was the same as in Fig. S1. NAI titer of trivalent immune sera. NA inhibition antibody titers against Mich15 (f), SL32 (g), and BCOL17 (h) were detected by ELLA. Neutralization titer of boost immune sera for trivalent vaccine. Microneutralization titers against CA09 (i), SL32 (j), and BCOL17 (k) virus were detected by microneutralization assay. Data are presented as the mean ± SD (n = 5), and each symbol represents one animal. The dashed lines correspond to the lowest initial dilution. Statistical significance was performed by One-way ANOVA; Unpaired Student’s t tests were used to compare antibody titers between prime and boost sera within the same dosage group of mice; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ns, not significant.

Sera antibody titers demonstrated that the trivalent circRNA vaccine induced a balanced and robust antibody response against all three NA components, comparable to monovalent vaccines (Fig. 4b–d). Importantly, there was no significant difference in sera titers between the two dose groups of the trivalent vaccine, possibly due to the saturation of circRNA doses in mice. Notably, trivalent vaccination elicited broader antibody recognition, encompassing all heterologous N1, N2, and IBV strains, exceeding the monovalent response, especially in the high-dose groups (Figs. 2e–g, 4e). Additionally, trivalent sera demonstrated functional neutralization against all three NA subtypes and their respective viruses in vitro (Fig. 4f–k).

Trivalent circRNA vaccine provided broad-spectrum protection in vivo

To assess in vivo protection, mice vaccinated with the trivalent circRNA vaccine were challenged with lethal doses of various influenza strains 28 days after the boost. Against the 5 × LD50 of homologous H1N1 strain A/California/04/2009 (CA09), both doses of the trivalent vaccine completely protected all mice, with minimal (~5%) weight loss (Fig. 5a). Even against a more distant H1N1 strain (A/Puerto Rico/8/1934; PR8; 81.8% identity), both doses provided significant protection, although with moderate (~15%) weight loss (Fig. 5b). Similar results were observed for H3N2 strains, with complete protection against the closer A/Gui Zhou/54/1989 (GZ89; 90.4% identity) and the more distant A/Hong Kong/8/1968 (HK68; 85% identity) strains (Fig. 5c, d). The vaccine’s role in dampening viral load was further evaluated. At 4 days post-infection (4 dpi), viral load in the lungs of vaccinated mice was significantly lower compared to control groups under the sublethal challenge with CA09 and HK68 strains (Fig. S3a, b).Fig. 5 Trivalent circRNA vaccine protects mice from heterologous virus challenge.

a–e Mice (n = 5) were immunized with 6 μg or 30 μg trivalent CircRNA vaccine in two doses at 28-day intervals. Blank LNP was used as a control. Twenty-eight days post boost vaccination, mice were challenged 5 × LD50 of A/California/04/2009(H1N1) (a), A/Puerto Rico/8/1934 (H1N1) (b), A/Gui Zhou/54/89 (H3N2) (c), A/Hong Kong/8/1968 (H3N2) (d), B/Colorado/06/2017(Victoria) (e). Body weight and survival rate were monitored for 14 days. Body weight was shown as the mean of five mice ± SD.

Similarly, the protective efficacy of the trivalent circRNA vaccine against influenza B virus was also evaluated. Upon the lethal challenge with B/Colorado/06/2017 (BCOL17; homologous to vaccine antigen), mice vaccinated with the trivalent circRNA vaccine were protected from morbidity (Fig. 5e). Lung virus titers were also analyzed at 4 dpi following sublethal challenge with 1 × LD50 of B/Malaysia/2506/2004 (BMA04; 96.6% identity) virus. Virus load in the lungs of all mice vaccinated with the trivalent circRNA vaccines was cleared below the detection limit, whereas virus load in the control group reached up to 105 PFU (Fig. S3d). The vaccine’s protective efficacy against the Yamagata lineage virus B/Florida/4/2006 was evaluated. At 4 dpi, viruses were effectively cleared in mice vaccinated with the trivalent vaccine, particularly in the high-dose group, while viral loads in lung homogenates of control mice exceeded 2 × 105 TCID50/ml (Fig. S3c). These findings indicate that the trivalent circRNA vaccine effectively protects mice against diverse strains of H1N1 and H3N2, as well as both Victoria and Yamagata influenza B viruses. These findings highlight the potential value of this platform for developing broad-spectrum influenza vaccines.

One dose of trivalent circRNA vaccines could protect mice

The protective efficacy of the trivalent circRNA vaccine was evaluated in a single-dose vaccination regimen (Fig. 6a). Mice that received a single dose of the trivalent circRNA vaccine at 30 μg and 6 μg doses survived the lethal challenge with B/Colorado/06/2017 (Fig. 6e). These results confirm that trivalent circRNA vaccines effectively protect mice with a single shot.Fig. 6 Protective efficacy of a single dose of circRNA vaccine.

a Immunization schedule for the challenge experiment in the prime-only group. The figure was created by the author using Adobe Illustrator 2020. b–d Antibody titers against the NA recombinant proteins from Mich15 (c), SL32 (d), and BCOL17 (e) were measured using ELISA. The data present results from five mice per group. Dashed lines indicate the lowest initial dilution. Statistical significance was determined using One-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns denotes not significant. e Mice (n = 5) in the prime-only group were challenged with 5 × LD50 of B/Colorado/06/2017 (Victoria) virus. Body weight and survival rate were monitored for 14 days. Body weight was shown as the mean of five mice ± SD.

Discussion

Developing a broad-spectrum influenza vaccine remains a major challenge. Current vaccines primarily target the highly variable HA protein, leading to reduced effectiveness against drifted influenza virus strains. In this study, we designed a circRNA vaccine based on the NA antigen. While NA exhibits less antigenic variation than HA, it is naturally an immune-subdominant antigen. On the surface of the influenza virus, HA is present in greater abundance than NA37. This means the immune system often prioritizes HA responses, potentially neglecting conserved NA epitopes. Previous studies successfully induced anti-NA antibodies using enhanced immunization strategies but struggled to target conformational epitopes crucial for neutralization38. Since most of the conserved B cell epitopes of NA depend on natural conformation, inducing antibodies towards these conformational epitopes remained a significant challenge.

To address this challenge, we utilized circRNA technology to deliver membrane-bound NA as the immunogen. Antigens encoded by circRNA mimic the natural conformation in the natural infection, thereby preserving key epitopes. Considering the safety of the vaccine, we chose a clinically validated LNP formulation. In our study, SM102-based LNPs were effective in delivering circRNA, and the safety profile is crucial for facilitating future clinical translation of the vaccine. A similar strategy has proven successful in mRNA vaccines, incorporating components such as HA stalk, NA, matrix-2 ion channel, and nucleoprotein in multivalent mRNA vaccines that induced protective effects against multi-strain influenza viruses20. Compared to mRNA, circRNA offer increased cellular stability due to their closed-loop structure24. This extended antigen presence could enhance B cell maturation and production of high affinity antibodies. These results confirm robust NA-specific antibody responses in mice receiving monovalent and trivalent circRNA vaccines (Figs. 2, 4).

Following booster immunization in this study, the vaccine induced a robust NA-reactive antibody response, as evidenced by high NAI antibody titers exceeding 1000 (Fig. 4f–h). These results suggest that boost immunization may be necessary to generate sufficient antibodies against enzyme-active sites. Unlike mice with a naive immune background, the population has preexisting low levels of NA-reactive antibodies39. This suggests the potential of utilizing this immune memory to enhance a robust immune response through an appropriate vaccination strategy. Future experiments should systematically evaluate how circRNA vaccines induce immune responses in mice previously exposed to influenza. A single dose of circRNA vaccine has the potential to reactivate NA-specific immune memory, but further experimental validation of this hypothesis is crucial.

CircRNA vaccine induced NAI antibodies against BCOL17, which is genetically closely related to the vaccine strain (Fig. S1) and can inhibit virus replication in vitro and in vivo. Although cross-reactive antibodies within the same subtype were induced, no cross-reactive between subtypes was observed, consistent with previous findings on NA-specific responses40. This highlights the ongoing challenge of eliciting broad-spectrum immunity against heterologous NA strains. Future strategies may involve incorporating more NA subtypes or designing immunogens focused on highly conserved enzyme active sites.

NA vaccines can still confer protection even when neutralization is limited20. Beyond humoral immunity, this study also revealed a robust T cell response induced by the circRNA vaccines. However, the CD8+ T cell response to SL32 N2 was less robust than that of N1 and BV (Fig. 3f). IFN-γ levels were higher than IL-4, indicating a Th1-biased immune response (Fig. 3a–e). This is further supported by the increased IgG2a: IgG1 ratio in vaccinated mice (Fig. S4). Th1-biased response with higher IgG2a level was known to be beneficial for clearing virus infections and reducing the risk of vaccine-associated enhanced respiratory disease (VAERD)41–44. While the role of NA-specific T cells has been relatively underexplored in previous studies, recent research on mRNA vaccines has highlighted their potential importance20. Similar cross-protection against heterologous strains such as GZ89, PR8, and HK68 was observed in this study. Although the trivalent circRNA vaccine sera did not neutralize these strains (Fig. S5), vaccinated mice exhibited complete survival upon challenge. Furthermore, Fc-mediated effector responses, such as ADCC, antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), may also contribute to vaccine protection45,46. The limitation of this study was the need to characterize these effects further. NA, as a membrane protein, simultaneously stimulates T cell response, NAI antibodies, and Fc-mediated effector functions such as ADCC, CDC, and ADCP are likely to play a more comprehensive protective role, offering broad protection against a wide range of strains.

The trivalent vaccines provided protection to mice with a single dose (Fig. 6). Given that a multi-dose immunization process may decrease public acceptance, this suggests that a prime-only approach can serve as an alternative vaccination regimen. Furthermore, the vaccine exhibited protection against Yamagata lineage viruses even in the absence of specific Yamagata lineage antigens (Fig. S3c). Sequence analyses between the vaccine’s N2 antigen and prevalent N2 strains suggest that the trivalent circRNA vaccine could be effective against contemporary H3N2 strains due to their closer antigenic resemblance compared to the GZ89 and HK68 strains (Fig. S6). These findings highlight the potential of this vaccine as a promising candidate for the seasonal influenza vaccines.

In conclusion, this study demonstrates the feasibility of delivering combined NA immunogens through circRNA technology to achieve broad-spectrum protection. The trivalent circRNA vaccine effectively protected mice against diverse H1N1, H3N2, and influenza B viruses. This protection likely involves a combination of NAI, Fc-mediated effector functions, and NA-specific T cell responses. These findings reinforce the potential of circRNA as a promising platform for influenza vaccines and highlight the importance of NA in developing universal vaccines. By building upon this work, circRNA can demonstrate its potential as a platform for broad-spectrum vaccines.

Methods

Cells

The human embryonic kidney (HEK) 293 T cells, Spodoptera frugiperda (Sf9) insect cells, and Madin Darby Canine Kidney (MDCK) cells were purchased from the American Type Culture Collection (ATCC). The HEK293T and MDCK cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, U.S.) supplemented with 10% fetal bovine serum (FBS, Gibco, U.S.) and 1% penicillin-streptomycin solution (Gibco, U.S.) at 37 °C with 5% CO2. The Sf9 cells were cultured in SF-SFM medium (Suzhou world-medium Biotechnology Co., Ltd., Suzhou, China) supplemented with 1% penicillin-streptomycin solution (Gibco, U.S.), at 27 °C in the dark, using a cell shaker setting at 110 rpm.

Virus and recombinant NA protein

All influenza viruses were grown in 10-day-old specific-pathogen-free (SPF) embryonated chicken eggs. Influenza A virus was cultured at 37 °C for 48 h, while influenza B virus was cultured at 33 °C for 72 h. Then the eggs were chilled at 4 °C overnight. The next day, the allantoic fluid was harvested, filtered, and centrifuged at the speed of 10,000 × g at 4 °C for 10 min. Finally, the virus was stored at −80 °C. Virus titer was determined by TCID50 assay. To prepare the virus for the challenge experiment, the collected allantoic fluid was ultracentrifuged on an Optima XPN-100 ultracentrifuge (Beckman, U.S.) at the speed of 130,000 × g at 4 °C for 2 h to precipitate the virus. The virus pellet was resuspended in 1 × phosphate-buffered saline (PBS) and further purified by passing through a 30% sucrose cushion. The purified virus was aliquoted and stored at −80 °C.

All recombinant NAs were expressed in the Sf9 cells, as described in the previous study47. Recombinant NAs were purified by Ni+ Sepharose high-performance chromatography.

CircRNA design and synthesis

CircRNA was generated using the PIE splicing strategy23. Linear precursor RNAs were transcribed from linearized plasmid templates using T7 RNA polymerase (Thermo, U.S.). After treatment with DNase I (New England Biolabs, USA), RNAs were purified using an RNA purification kit (Magen Biotechnology Co., Ltd., Guangzhou, China). For the RNA cyclization reaction, purified RNA was first heated to 70 °C for 5 min and immediately placed on ice. The reaction solution was added, containing a final concentration of 2 mM Guanosine triphosphate (GTP), 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, and 1 mM DTT. The RNA cyclization reaction was performed at 55 °C for 8 min, then RNase R (New England Biolabs, USA) was added to the reaction and incubated at 37 °C for 15 min to remove uncirculated RNA. CircRNA was finally column purified using the RNA purification kit (Magen Biotechnology Co., Ltd., Guangzhou, China) and stored at −80 °C. According to the previous study23, the quality and integrity of circRNAs were assessed by 1.5% agarose gel electrophoresis at 160 V for 30 min.

LNP encapsulated circRNA

LNPs were generated by rapidly mixing the organic and aqueous phases (1:3, v/v) through the iNanoE microfluidic system (Micro & Nano (Shanghai) Biologics Co. Ltd., Shanghai, China) at a total flow rate of 12 mL/min. The organic phase was formed by mixing SM102, 1,2-Distearoyl-sn-glycero-3-phosphorylcholine (DSPC), cholesterol, and DMG-PEG2000 (AVT (Shanghai) Pharmaceutical Tech Co., Ltd) in ethanol with a molar ratio of 50:10:38.5:1.5. The circRNA was dissolved in 50 mM citric acid buffer (pH = 4). The N/P ratio of ionizable lipids and circRNA was 4:1. The formed LNPs were diluted 40-fold in PBS and concentrated using a 100 kDa ultrafiltration tube (Millipore, U.S.). The encapsulation efficiency of LNP was determined following the method described previously48. To characterize particle size and PDI, LNPs were added to the cuvette after 40-fold dilution by PBS, and dynamic light scattering (DLS) was performed using Zetasizer Pro (Malvern Panalytical, England), with three replicates of measurements for each sample, and PBS as a negative sample control.

CircRNA-LNP transfection and flow cytometric analyses

Before transfection, HEK293T cells were seeded in 24-well plates at a density of 6 × 105. The following day, 500 ng of each LNP encapsulated circRNA was diluted in DMEM and added to cells. After 48 h, the cells were harvested and washed with 1% Bovine Serum Albumin (BSA) Fraction V in 1 × PBS. Then cells were incubated with 10 μg/mL anti-NA antibodies: 1G01, 229-2C06, or CC61 for 20 min on ice. After that, cells were washed twice with 1% BSA PBS and incubated with 1: 2000 dilution of rabbit anti-human IgG(H + L) FITC (Southern Biotech, U.S.) for 20 min on ice in the dark. Cells were washed twice and resuspended. Flow cytometric data were acquired on CytoFLEX S flow cytometer (Beckman, U.S.). Approximately 50,000 events were collected per sample.

MUNANA assay

LNP transfected cells were diluted at the density 1 × 106 in MUNANA buffer (33.3 mM MES, 4 mM CaCl2, pH 6.5). The cells were two-fold serially diluted using MUNANA buffer in a black 96-well plate to make a 50 μL final volume. Then, 50 μL of 300 μΜ of MUNANA substrate was added. After incubating at 37 °C for 1 h, 100 μL of stop solution (138.6 mM NaOH in absolute ethanol) was added. The plate was read using a SYNERGY H1 (BioTek, US) multimode microplate reader with 355 nm excitation and 460 nm emission.

Vaccination and virus challenge

6–8-week-old female BALB/c mice (n = 5 per group) were intramuscularly injected with 100 μL circRNA vaccine diluted in PBS. Trivalent circRNA vaccines were formulated with equal amounts of three NA circRNA vaccines. Boost vaccination was performed 28 days after prime vaccination. Twenty-eight days after boost vaccination, mice were anesthetized with avertin (250 mg/kg) and intranasally infected with 5 × LD50 influenza virus in 30 μL PBS. The body weight was monitored for 14 days after infections, and mice that lost over 25% of their initial weight were humanely euthanized. The weighing order was randomly assigned each day, and each group of mice was weighed in a different order each day. The animals were grouped and manipulated by different individuals. The experimental operators were unaware of the specific grouping. All mice were kept in a SPF environment, and all virus challenge experiments were performed in an animal biosafety level 2 laboratory.

For the euthanasia of mice, animals were initially anesthetized with Avertin (250 mg/kg) via intraperitoneal injection. Subsequently, euthanasia was carried out by cervical dislocation after confirming their lack of responsiveness to pain and stimuli (deep anesthesia). Euthanasia was carried out following the American Veterinary Medical Association (AVMA) Guidelines.

ELISA

The 96-well ELISA plates were coated with recombinant NA proteins (50 μL, 200 ng/well) or trivalent inactivated vaccine (TIV, Southern hemisphere, 2022-2023) in PBS at 4 °C overnight. The following day, the plates were blocked with 150 μL 3% BSA at 37 °C for 1 h. The sera were serially diluted 3-fold, starting with a 1:300 dilution (or 1:100 in the prime group for Fig. 6), and then added to the plates. The plates were subsequently incubated at 37 °C for 1 h. Following washing with PBST (PBS added with 0.05% TWEEN 20), 75 μL of 1: 4000 dilution of HRP-conjugated anti-mouse IgG/IgG1/IgG2a secondary antibody (Southern Biotech, U.S.) was added to plates and incubated at 37 °C for 1 h. The readout was developed using 2,2’-Azino-bis (3-Ethylbenzthiazoline-6-Sulfonic Acid, ABTS) ELISA substrate (sigma, U.S.). After 20 min of incubation, absorbance was measured at 405 nm on a Spectramax ABS Plus (Molecular Devices, U.S.) microplate reader. Endpoint titers were defined as the dilution fold with OD value exceeding 2 × background (without sera, but the secondary antibody was added). Monoclonal antibody 1G0110 was used as positive control.

Enzyme-linked lectin assay (ELLA)

The 96-well ELISA plates were pre-coated with 100 μL of fetuin (Sigma, U.S.) at 25 μg/mL in PBS and incubated at 4 °C for 24 h, then the plates were washed three times with PBST. Heat-inactivated sera were 2-fold serially diluted starting with a 1:50 dilution (in some groups were 1:100) in DPBS-T-BSA buffer (Dulbecco’s phosphate-buffered saline containing 0.133 g/L CaCl2 and 0.1 g/L MgCl2 with 0.05% Tween-20 and 1% BSA) and mixed with an equal volume of virus or NA recombinant proteins. The mixtures were incubated at 37 °C for 2 h and then transferred to the fetuin-coated plates. The plates were incubated at 37 °C for 18 h and washed six times with PBST subsequently. Then 100 μL/well of HRP-conjugated peanut agglutinin lectin (Sigma, U.S.) in PBS was added to the plates and left in the dark for 2 h at room temperature. After adding the ABTS ELISA substrate and 15 min of incubation, the absorbance of the samples was read at 405 nm on a Spectramax ABS Plus (Molecular Devices, U.S.) microplate reader. The samples that did not reach 50% inhibition at the initial sera dilution were considered negative.

Microneutralization assay

For the microneutralization assay, sera were treated with the receptor-destroying enzyme (RDE, Denka Seiken, Japan) and then inactivated at 56 °C for 30 min. Sera were then diluted 2-fold serially starting at 1:10 dilutions in infection media (DMEM supplemented with 1 μg/mL TPCK-treated trypsin, 0.1 mM MEM non-essential amino acid, 1% penicillin-streptomycin solution). Next, 60 μL of diluted sera were mixed with 60 μL of 100 × TCID50 virus and incubated at 37 °C for 1 h. Then the virus-sera mixtures were transferred to the PBS-washed MDCK cells and incubated at 37 °C with 5% CO2 for 1 h. After washing with PBS twice, 100 μL of infection medium with the same sera dilution was added to the cells. Following incubation at 37 °C for 48 h (for influenza A virus) or 33 °C for 72 h (for influenza B virus). Virus replication was detected using a hemagglutination assay. Briefly, 50 μL of cell supernatant was transferred into a 96-well V-bottom plate, followed by the addition of 25 μL of 1% chicken red blood cells (RBCs). After incubating at room temperature for 15 mins, the presence of virus was determined by observing hemagglutination of the RBCs. The neutralization titer of sera was determined as the highest dilution at which no virus was detected.

ELISPOT assay

The day before assay, 1:100 anti-mouse IFN-γ or IL-4 antibody (U-Cytech, Netherland) was added to ELISpot plate (Millipore, U.S.) and incubated at 4 °C overnight. The Next day, plates were blocked with 10% FBS in RPMI 1640 medium at 37 °C for 1 h. Next 4 × 105 Splenocytes were added to the ELISPOT plate and stimulated by 10 μg/mL recombinant NA protein at 37 °C in 5% CO2 for 40 h. The plates were washed with PBST 6 times and incubated with 1:100 biotinylated antibody for 2 h at RT. After washing, the plates were incubated with 1:500 Streptavidin-HRP for 1 h at RT. Finally, the plates were incubated with 5-bromo-4chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/NBT, Beyotime, China) substrate solution for 5 min, and scanned using Mabtech IRIS FluoroSpot/ELISpot reader (Mabtech, Sweden).

Intracellular cytokine staining assay

The splenocytes were isolated and plated at a density of 4 × 106 per well in a round-bottom 96-well plate and stimulated with 10 μg/mL recombinant NA protein at 37 °C, 5% CO2 for 6 h. Brefeldin A was then added to each sample and cells were incubated for an additional 4 h. After incubation, cells were washed with PBS and stained with LIVE/DEAD cell staining solution (Biolegend, U.S.) for 30 min in the dark. After washing with FASC buffer (PBS added 2% FBS), cells were then incubated with Fc Blocker (Biolegend, #101319, U.S.) for 5 min in dark and then surface-stained with the following antibodies: anti-CD3-Pacific Blue™ (Biolegend, #100214, U.S.); anti-CD4-FITC (Biolegend, #100509, U.S.); anti-CD8α-Brilliant Violet 605 (Biolegend, #100744, U.S.). After fixation with a fixation/permeabilization solution (Beyotime, China), cells were intracellularly stained with the following antibodies: anti-IFN-γ-APC (Biolegend, #505810, U.S.); anti-TNF-α-Brilliant Violet 785™ (Biolegend, #506341, U.S.); anti-IL-2-PE-Cyanine7 (Biolegend, #503832, U.S.) for 30 min in dark. Finally, cells were washed twice using permeabilization buffer and suspended in FASC buffer. Flow cytometric analysis and cell sorting were performed on CytoFLEX S Flow Cytometer (Beckman Coulter, U.S.). Analysis was performed using FlowJo software V_10.

Virus plaque assay and TCID50 assay

Mice were sacrificed and lungs were homogenized in 10% (w/v) DMEM at 4 dpi. The lung homogenate was diluted in a 1:10 series and inoculated into a 6-well plate containing a single layer of MDCK cells. After 1 h of incubation, the plates were washed twice with PBS and 2 mL overlay (2 × DMEM, 1 μg/mL TPCK-treated trypsin, 0.1 mM MEM non-essential amino acid, 1% penicillin-streptomycin solution, 0.8% low melting agar) was added. After 72 h of culture, the agar overlays were removed, and the cells were fixed and stained with a crystal violet solution.

To determine the TCID50, the lung homogenate was 3-fold serially diluted in DMEM starting at 1:10. MDCK monolayers in 96-well plates were washed twice with PBS before adding 100 μL of the diluted lung homogenate. After incubating at 37 °C with 5% CO2 for 1 h, cells were washed with PBS, followed by adding 100 μL of infection media. Influenza A virus-infected cells were further cultured at 37 °C with 5% CO2 for 48 h, while influenza B virus-infected cells were incubated at 33 °C with 5% CO2 for 72 h. Hemagglutination assay was performed as described in 10. TCID50 was calculated using the Reed-Muench method.

Phylogenetic tree analysis

All NA sequences involved in this study were downloaded from the NCBI database (https://www.ncbi.nlm.nih.gov/). NA phylogenetic tree was generated by MAGAX using the Maximum Likelihood method.

Statistical analysis

Statistical analyses were performed using the Prism 9.0 software (GraphPad, U.S.). All errors are expressed as means with standard derivation (±SD). In Figs. 2 and 4, one-way ANOVA with multiple comparison tests was employed to compare antibody titers among different groups within the prime or boost immunization phases. Unpaired Student’s t tests were used to compare antibody titers between prime and boost sera within the same dosage group of mice. Unpaired Student’s t test analysis was performed to determine p values in T cell responses. Group data were considered statistically significant when p < 0.05, and*, **, ***, ****, and ns in results represent p < 0.05, p < 0.01, p < 0.001, p < 0.0001, and not significant, respectively.

Supplementary information

Supplementary Information

Supplementary information

The online version contains supplementary material available at 10.1038/s41541-024-00963-4.

Acknowledgements

This work was supported in whole or in part by the National Key R&D Program of China (Grant number: 2022YFC2304204 to Y.-Q.C. 2021YFC2300100 and 2021YFC2300102 to Y.-L.S.), Shenzhen Medical Research Fund: B2302044 to Y.-Q.C., Shenzhen Science and Technology Program (Grant number: JCYJ2020010914243811 to Y.-L.S., JCYJ20190807154603596, KQTD20200820145822023 to Y.-Q.C.). National Natural Science Foundation of China (31970881 and 92169104 to Y.-Q.C.), CAMS Innovation fund for Medical Sciences grant 2022-I2M-1-021 to Y.-L.S. Science and Technology Planning Project of Guangdong Province, China (2021B1212040017). We thank the Experimental Teaching Centre of the School of Public Health (Shenzhen) for providing instrument support for this study.

Author contributions

X.Y., C.Z., S.L., and R.C. designed and performed experiments, analyzed data, and wrote the manuscript. Z.Q., Y.L., X.Z., M.Z., and H.M. assisted in the daily mice weighing. L.L., Y.Z, and W.L. prepared influenza viruses used in the mice challenge experiments. H.L. and Y.W. assisted in analyzing FASC data. Y.S. assisted in recombinant NA purification. M.X., S.L., and K.L. assisted in the format modification. J.L., L.D., Y.L., J.Y., and C.S. supplied critical materials and technical help. All authors reviewed and commented on the manuscript. Y.-Q.C., K.-W.Z., and Y.-L.S. conceived the project, supervised the work, and revised the manuscript.

Data availability

The authors declare that the data are publicly available or will be available upon request

Competing interests

The authors declare no competing interests.

Declaration of the use of Artificial Intelligence (AI) assisted technology in the manuscript writing

The authors utilized ChatGPT 3.5 to enhance grammar and readability during the manuscript writing. Following this, the authors thoroughly reviewed and edited the article, assuming full responsibility for its content.

Ethics

The Mice experiment proposal was examined and approved by the Institutional Animal Care and Use Committee (IACUC) from the Shenzhen Bay Laboratory. (Ethics File Code: AECYQ202201). Mice experiments were performed according to the animal welfare requirements of Shenzhen Bay Laboratory. Mice influenza virus challenge experiments were performed in the animal biosafety level 2 (ABSL-2) facility at Shenzhen Bay Laboratory.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Xinyu Yue, Cailing Zhong, Rui Cao, Sizhe Liu.
==== Refs
References

1. Wu NC Ellebedy AH Targeting neuraminidase: the next frontier for broadly protective influenza vaccines Trends Immunol. 2024 45 11 19 10.1016/j.it.2023.11.001 38103991
Wu, N. C. & Ellebedy, A. H. Targeting neuraminidase: the next frontier for broadly protective influenza vaccines. Trends Immunol. 45, 11–19 (2024).38103991 10.1016/j.it.2023.11.001
2. Krammer F NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 2018 9 e0233217 10.1128/mBio.02332-17
Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, e0233217 (2018).10.1128/mBio.02332-17
3. Zhang X Ross TM Anti-neuraminidase immunity in the combat against influenza Expert Rev. Vaccines 2024 23 474 484 10.1080/14760584.2024.2343689 38632930
Zhang, X. & Ross, T. M. Anti-neuraminidase immunity in the combat against influenza. Expert Rev. Vaccines 23, 474–484 (2024).38632930 10.1080/14760584.2024.2343689
4. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine. Vaccines 8, 10.3390/vaccines8030409 (2020).
5. Chen YQ Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies Cell 2018 173 417 429.e410 10.1016/j.cell.2018.03.030 29625056
Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429.e410 (2018).29625056 10.1016/j.cell.2018.03.030
6. Momont C A pan-influenza antibody inhibiting neuraminidase via receptor mimicry Nature 2023 618 590 597 10.1038/s41586-023-06136-y 37258672
Momont, C. et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature 618, 590–597 (2023).37258672 10.1038/s41586-023-06136-y
7. Hansen L Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo Immunity 2023 56 1927 1938.e1928 10.1016/j.immuni.2023.07.004 37506693
Hansen, L. et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity 56, 1927–1938.e1928 (2023).37506693 10.1016/j.immuni.2023.07.004
8. Lei R Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase Immunity 2023 56 2621 2634.e2626 10.1016/j.immuni.2023.10.005 37967533
Lei, R. et al. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Immunity 56, 2621–2634.e2626 (2023).37967533 10.1016/j.immuni.2023.10.005
9. Lederhofer, J. et al. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity, 10.1016/j.immuni.2024.02.003 (2024).
10. Stadlbauer D Broadly protective human antibodies that target the active site of influenza virus neuraminidase Science 2019 366 499 504 10.1126/science.aay0678 31649200
Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499–504 (2019).31649200 10.1126/science.aay0678
11. Tan J Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the Guinea Pig Model J. Virol. 2022 96 e0142121 10.1128/JVI.01421-21 34669506
Tan, J. et al. Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the Guinea Pig Model. J. Virol. 96, e0142121 (2022).34669506 10.1128/JVI.01421-21
12. McMahon M Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner J. Virol. 2023 97 e0105723 10.1128/jvi.01057-23 37800945
McMahon, M. et al. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner. J. Virol. 97, e0105723 (2023).37800945 10.1128/jvi.01057-23
13. Memoli MJ Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model mBio 2016 7 e00417 00416 10.1128/mBio.00417-16 27094330
Memoli, M. J. et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. mBio 7, e00417–00416 (2016).27094330 10.1128/mBio.00417-16
14. Strohmeier S A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice NPJ Vaccines 2022 7 81 10.1038/s41541-022-00486-w 35869085
Strohmeier, S. et al. A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. NPJ Vaccines 7, 81 (2022).35869085 10.1038/s41541-022-00486-w
15. Johansson BE Matthews JT Kilbourne ED Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response Vaccine 1998 16 1009 1015 10.1016/S0264-410X(97)00279-X 9682352
Johansson, B. E., Matthews, J. T. & Kilbourne, E. D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16, 1009–1015 (1998).9682352 10.1016/S0264-410X(97)00279-X
16. Strohmeier S A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model mBio 2021 12 e0224121 10.1128/mBio.02241-21 34809451
Strohmeier, S. et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. mBio 12, e0224121 (2021).34809451 10.1128/mBio.02241-21
17. Gao J Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone PLoS Pathog. 2021 17 e1009171 10.1371/journal.ppat.1009171 33872324
Gao, J. et al. Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone. PLoS Pathog. 17, e1009171 (2021).33872324 10.1371/journal.ppat.1009171
18. Broecker, F. et al. Extending the stalk enhances immunogenicity of the influenza virus neuraminidase. J. Virol. 93, 10–1128 (2019).
19. Chivukula S Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza NPJ Vaccines 2021 6 153 10.1038/s41541-021-00420-6 34916519
Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines 6, 153 (2021).34916519 10.1038/s41541-021-00420-6
20. Freyn AW A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice Mol. Ther. 2020 28 1569 1584 10.1016/j.ymthe.2020.04.018 32359470
Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569–1584 (2020).32359470 10.1016/j.ymthe.2020.04.018
21. McMahon M Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses Proc. Natl. Acad. Sci. USA 2022 119 e2206333119 10.1073/pnas.2206333119 36322769
McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl. Acad. Sci. USA 119, e2206333119 (2022).36322769 10.1073/pnas.2206333119
22. Pardi N Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses Nat. Commun. 2022 13 4677 10.1038/s41467-022-32149-8 35945226
Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).35945226 10.1038/s41467-022-32149-8
23. Wesselhoeft RA Kowalski PS Anderson DG Engineering circular RNA for potent and stable translation in eukaryotic cells Nat. Commun. 2018 9 2629 10.1038/s41467-018-05096-6 29980667
Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).29980667 10.1038/s41467-018-05096-6
24. Qu L Circular RNA vaccines against SARS-CoV-2 and emerging variants Cell 2022 185 1728 1744.e1716 10.1016/j.cell.2022.03.044 35460644
Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728–1744.e1716 (2022).35460644 10.1016/j.cell.2022.03.044
25. Amaya L Circular RNA vaccine induces potent T cell responses Proc. Natl. Acad. Sci. USA 2023 120 e2302191120 10.1073/pnas.2302191120 37155869
Amaya, L. et al. Circular RNA vaccine induces potent T cell responses. Proc. Natl. Acad. Sci. USA 120, e2302191120 (2023).37155869 10.1073/pnas.2302191120
26. Jansen JM Gerlach T Elbahesh H Rimmelzwaan GF Saletti G Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination J. Clin. Virol. 2019 119 44 52 10.1016/j.jcv.2019.08.009 31491709
Jansen, J. M., Gerlach, T., Elbahesh, H., Rimmelzwaan, G. F. & Saletti, G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J. Clin. Virol. 119, 44–52 (2019).31491709 10.1016/j.jcv.2019.08.009
27. Koutsakos M Human CD8+ T cell cross-reactivity across influenza A, B and C viruses Nat. Immunol. 2019 20 613 625 10.1038/s41590-019-0320-6 30778243
Koutsakos, M. et al. Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nat. Immunol. 20, 613–625 (2019).30778243 10.1038/s41590-019-0320-6
28. van de Ven K A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets Sci. Adv. 2022 8 eadc9937 10.1126/sciadv.adc9937 36516261
van de Ven, K. et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci. Adv. 8, eadc9937 (2022).36516261 10.1126/sciadv.adc9937
29. Koutsakos M Wheatley AK Laurie K Kent SJ Rockman S Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 2021 19 741 742 10.1038/s41579-021-00642-4 34584246
Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 19, 741–742 (2021).34584246 10.1038/s41579-021-00642-4
30. Sultana I Stability of neuraminidase in inactivated influenza vaccines Vaccine 2014 32 2225 2230 10.1016/j.vaccine.2014.01.078 24613525
Sultana, I. et al. Stability of neuraminidase in inactivated influenza vaccines. Vaccine 32, 2225–2230 (2014).24613525 10.1016/j.vaccine.2014.01.078
31. Weiss CD Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A/H3N2 outbreak among unvaccinated military recruits Clin. Infect. Dis. 2020 71 3096 3102 10.1093/cid/ciz1198 31840159
Weiss, C. D. et al. Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A/H3N2 outbreak among unvaccinated military recruits. Clin. Infect. Dis. 71, 3096–3102 (2020).31840159 10.1093/cid/ciz1198
32. Couch RB Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase J. Infect. Dis. 2013 207 974 981 10.1093/infdis/jis935 23307936
Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207, 974–981 (2013).23307936 10.1093/infdis/jis935
33. Corbett KS SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Nature 2020 586 567 571 10.1038/s41586-020-2622-0 32756549
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).32756549 10.1038/s41586-020-2622-0
34. Vogel AB BNT162b vaccines protect rhesus macaques from SARS-CoV-2 Nature 2021 592 283 289 10.1038/s41586-021-03275-y 33524990
Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021).33524990 10.1038/s41586-021-03275-y
35. Zhang NN A Thermostable mRNA Vaccine against COVID-19 cell 2020 182 1271 1283.e1216 10.1016/j.cell.2020.07.024 32795413
Zhang, N. N. et al. A Thermostable mRNA Vaccine against COVID-19. cell 182, 1271–1283.e1216 (2020).32795413 10.1016/j.cell.2020.07.024
36. Arevalo CP A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes Science 2022 378 899 904 10.1126/science.abm0271 36423275
Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).36423275 10.1126/science.abm0271
37. Harris A Influenza virus pleiomorphy characterized by cryoelectron tomography Proc. Natl. Acad. Sci. USA 2006 103 19123 19127 10.1073/pnas.0607614103 17146053
Harris, A. et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl. Acad. Sci. USA 103, 19123–19127 (2006).17146053 10.1073/pnas.0607614103
38. Liu D-J Boost immunizations with NA-derived peptide conjugates achieve induction of NA inhibition antibodies and heterologous influenza protections Cell Rep. 2023 42 112766 10.1016/j.celrep.2023.112766 37421618
Liu, D.-J. et al. Boost immunizations with NA-derived peptide conjugates achieve induction of NA inhibition antibodies and heterologous influenza protections. Cell Rep. 42, 112766 (2023).37421618 10.1016/j.celrep.2023.112766
39. Rajendran, M. et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin. mBio 8, 10–1128 (2017).
40. Walz, L., Kays, S. K., Zimmer, G. & von Messling, V. Neuraminidase-Inhibiting antibody titers correlate with protection from heterologous influenza virus strains of the same neuraminidase subtype. J. Virol. 92, 10–1128 (2018).
41. Hovden AO Cox RJ Haaheim LR Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice Scand. J. Immunol. 2005 62 36 44 10.1111/j.1365-3083.2005.01633.x 16092921
Hovden, A. O., Cox, R. J. & Haaheim, L. R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62, 36–44 (2005).16092921 10.1111/j.1365-3083.2005.01633.x
42. Moran TM Park H Fernandez-Sesma A Schulman JL Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection J. Infect. Dis. 1999 180 579 585 10.1086/314952 10438342
Moran, T. M., Park, H., Fernandez-Sesma, A. & Schulman, J. L. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J. Infect. Dis. 180, 579–585 (1999).10438342 10.1086/314952
43. Mozdzanowska K Furchner M Washko G Mozdzanowski J Gerhard W A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro J. Virol. 1997 71 4347 4355 10.1128/jvi.71.6.4347-4355.1997 9151823
Mozdzanowska, K., Furchner, M., Washko, G., Mozdzanowski, J. & Gerhard, W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71, 4347–4355 (1997).9151823 10.1128/jvi.71.6.4347-4355.1997
44. Graham BS Rapid COVID-19 vaccine development Science 2020 368 945 946 10.1126/science.abb8923 32385100
Graham, B. S. Rapid COVID-19 vaccine development. Science 368, 945–946 (2020).32385100 10.1126/science.abb8923
45. Kim KH Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle PLoS Pathog. 2022 18 e1010755 10.1371/journal.ppat.1010755 36006890
Kim, K. H. et al. Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle. PLoS Pathog. 18, e1010755 (2022).36006890 10.1371/journal.ppat.1010755
46. Wu Y A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus Nat. Commun. 2015 6 7708 10.1038/ncomms8708 26196962
Wu, Y. et al. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat. Commun. 6, 7708 (2015).26196962 10.1038/ncomms8708
47. Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. e51112, 10.3791/51112 (2013).
48. Seephetdee C A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera Antivir. Res. 2022 204 105370 10.1016/j.antiviral.2022.105370 35772601
Seephetdee, C. et al. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antivir. Res. 204, 105370 (2022).35772601 10.1016/j.antiviral.2022.105370
